Combination therapy doubles survival in metastatic lung cancer
The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to ...
Apr 16, 2018
0
6